Data as of May 20
| -3.33 / -1.25%|
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company markets two products: EYLEA (aflibercept) injection and ARCALYST (rilonacept) injection. EYLEA (aflibercept) injection which is used for the treatment of neovascular age related macular degeneration. ARCALYST (rilonacept) which is used for the treatment of Cryopyrin-Associated Periodic Syndrome including Familial Cold Auto-inflammatory Syndrome and Muckle-Wells Syndrome. The discovery platforms are designed to identify specific proteins of therapeutic interest for a particular disease or cell type and validate these targets through production of genetically modified mice using VelociGene technology. It has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia. The company was founded by Alferd G. Gilman, Leonard S. Schleifer and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.
|Leonard S. Schleifer, MD, PhD||President, Chief Executive Officer & Director|
|Murray A. Goldberg, MBA||CFO, Treasurer & Senior VP-Administration|
|Peter Powchik, MD||Senior Vice President-Clinical Development|
|William G. Roberts, MD||VP-Regulatory Development & Medical Safety|
|Neil Stahl, PhD||Senior VP-Research & Development Sciences|